DOCSLIB.ORG

Etoricoxib: a Safe Alternative for NSAID Intolerance in Asian Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Etoricoxib: a Safe Alternative for NSAID Intolerance in Asian Patients Short communication Etoricoxib: a safe alternative for NSAID intolerance in Asian patients Genevieve V. Llanora,1 Evelyn Xiu Ling Loo,2 Irvin Francis A. Gerez,1 Yew Kuang Cheng 3,4 and Lynette P. Shek 1,2 Summary the patients had multiple symptoms on presentation, the most common of which were Background: NSAID intolerance is not uncommon. periorbital and facial edema (90%), breathing Etoricoxib, a cox-2 inhibitor NSAID, has been difficulties (26%) and urticaria (25%), with the shown to be a safe alternative in these patients. onset of reaction occurring mostly within 30 This study aims to determine the rate of NSAID minutes to 1 hour. Etoricoxib was tolerated in intolerant patients who are able to tolerate 95% of the patients. Subjects who reacted to the etoricoxib without adverse reactions. challenge all had mild reactions which resolved Methods: This study analyzed charts and with antihistamines. electronic databases of all patients referred to the Conclusions: Etoricoxib is a safe alternative in allergy clinics of the National University Hospital NSAID intolerant patients. Nevertheless, it is and Gleneagles Hospital in Singapore from 2006- advised that patients should undergo provocation 2011 for oral provocation tests to etoricoxib tests to confirm tolerance. (Asian Pac J Allergy (cumulative dose of 120mg), on the background Immunol 2013;31:330-3) of NSAID intolerance. Demographics, atopic comorbidities, history of chronic urticaria, Key words: Non-steroidal anti-inflammatory drug, inciting NSAID, onset and type of reaction, and drug reaction, oral provocation test provocation test outcomes were obtained. Introduction Results: A total of 74 patients (mean age 37; Non-steroidal anti-inflammatory drugs (NSAIDs) range: 16-72 years) underwent provocation tests are medications commonly used to alleviate pain to etoricoxib. Of these, 59% were female. and inflammation. It is estimated that over 30 Majority were Chinese (69%), followed by Malay million people worldwide consume it, with the trend (12%), Caucasian (8%), Indian (5%) and various increasing in the past 20 years. 1,2 The prevalence of other races (6%). Forty-six percent of the study NSAID intolerance ranges from 0.6-2.5% in the population had atopic comorbidities, and 4% had general population, to as high as 30% in patients concomitant chronic urticaria. Eighty percent of with asthma, nasal polyposis, and chronic idiopathic patients had a history of intolerance to 1 NSAID, urticaria. 2,3 In different populations, it currently while the rest (20%) had intolerance to multiple ranks second or third to the beta-lactam antibiotics NSAIDS. Forty-one percent of patients had in producing “allergic-type” drug reactions. concomitant acetaminophen intolerance. Some of NSAID-induced reactions can be classified as immunologic and non-immunologic. Immunologic From 1. University Children’s Medical Institute, National reactions can be in the form of an immediate University Hospital, Singapore hypersensitivity reaction (IgE mediated), or a type 2. Department of Paediatrics, Yong Loo Lin School of IV allergic reaction through drug-specific cytotoxic 2 Medicine, National University of Singapore T cells. For NSAIDS, the most well described 3. Department of Medicine, Yong Loo Lin School of reaction is non-immunologic and involves inhibition Medicine, National University of Singapore of the 2 isoforms of the cyclooxygenase enzyme 4. Gleneagles Medical Centre, Singapore (cox-1 and cox-2), thereby decreasing the production of Corresponding author: Genevieve V. Llanora potent inflammatory mediators, namely prostaglandin 2,4 E-mail: [email protected] and thromboxane. Inhibition of prostaglandin Submitted date: 22/8/2012 induces mast cell degranulation. With the inhibition Accepted date: 6/11/2012 of the cyclooxygenase pathway, the lipooxygenase pathway is favored, producing leukotriene, which 330 Etoricoxib is safe for NSAID intolerant patients promotes bronchoconstriction. 5 These mechanisms patients had multiple symptoms upon ingestion of are responsible for the signs and symptoms the inciting NSAID. The most common symptoms exhibited by NSAID intolerant patients. on presentation were periorbital and facial edema The therapeutic effects are primarily related to (90%), breathing difficulties (26%) and urticaria their ability to inhibit the cox-2 pathway, and the (25%), with the onset of reaction occurring mostly most frequent adverse effects are caused by cox-1 within 30 minutes to 1 hour. As some patients with inhibition. 4 It has been thought that specific cox-2 NSAID intolerance have concomitant acetaminophen inhibitor NSAIDs such as etoricoxib can be a intolerance, the history of concurrent acetaminophen potential safe alternative for patients with adverse intolerance was also determined. However, the reactions to NSAIDs. Indeed, this has been shown in definite dose that triggered the reaction was not 2 previous studies where most of the NSAID stated, as these were only obtained from medical intolerant patients who underwent provocation tests records, and not proven by provocation tests. It were able to tolerate etoricoxib. 6,7 showed an incidence rate of 41%, comparable to the In Asia, the exact prevalence of NSAID study done by Borges and Hulett, where 32% of intolerance is unknown. Furthermore, there are no patients with NSAID intolerance reacted to studies or reports on the tolerability to etoricoxib acetaminophen during provocation testing. 8 Table 1 among these patients. Thus, this is the first study in describes the general characteristics if the study Asia that aims to determine the safety of using population. etoricoxib in NSAID-intolerant patients. Table 1. General characteristics of the study population Methods Concomitant etoricoxib This study reviewed charts and electronic intolerance databases of all patients referred for NSAID YES NO P- intolerance to two allergy units in Singapore, one at 4/74 70/74 value the National University Hospital (NUH) and the (5%) (95%) other at Gleneagles Medical Centre (GMC), from Atopic comorbidities 2006-2011. These patients underwent oral Positive* 34/74 3/4 31/70 0.328 provocation tests to a cumulative dose of 120 mg of (46%) (75%) (44%) etoricoxib. In NUH, etoricoxib was given in 3 -Asthma 3/4 11/70 0.515 divided doses, 30 minutes apart(1 st dose: 30mg, 2 nd (25%) (16%) dose: 30mg, 3 rd dose: 60mg) whereas in GMC, it -Allergic rhinitis 3/4 21/70 0.097 was given in 4 divided doses (1 st dose: 15mg, 2 nd (75%) (30%) dose: 15mg, 3 rd dose: 30mg, 4th dose: 60mg). -Atopic dermatitis 1/4 4/70 (6%) 0.249 Information such as demographic data, atopic (25%) comorbidities, history of chronic urticaria, inciting Negative 40/74 1/4 39/70 0.328 (54%) (25%) (56%) NSAID, onset and type of reaction, presence or Chronic 3/74 1/4 2/70 (3%) 0.156 absence of concomitant acetaminophen intolerance, urticaria (4%) (25%) and provocation test outcomes were obtained. This Reaction study was approved by the Institutional Review To single NSAID 59/74 2/4 57/70 0.181 Board (NHG Domain Specific Review Board; (80%) (50%) (81%) Reference number 2011/01851). To multiple 15/74 2/4 13/70 0.181 NSAIDs (20%) (50%) (19%) Results Type of reactions to NSAIDS+ A total of 74 patients (mean age 37; range: 16-72 Cutaneous signs years) underwent provocation tests to etoricoxib. Of and symptoms these, 59% were female. Majority were Chinese Periorbital and 66/74 3/4 63/70 0.374 (69%), followed by Malay (12%), Caucasian (8%), facial edema (90%) (75%) (90%) Indian (5%) and various other races (6%). Forty-six Urticaria 18/74 1/4 17/70 1.000 (25%) (25%) (24%) percent of the study population had atopic Breathing 19/74 0 19/70 0.567 comorbidities, and 4% had concomitant chronic difficulties (26%) (27%) urticaria. Eighty percent of patients had a history of *Some patients have multiple comorbidities intolerance to 1 NSAID, while the rest (20%) had +Some patients presented with multiple signs and symptoms intolerance to multiple NSAIDS. Some of the 331 Asian Pac J Allergy Immunol 2013;31:330-3 DOI10.12932/AP0290.31.4.2013 Table 2. Clinical characteristics of eto ricoxib intolerant patients Cumulative History Patient Drug Concomitant OPT with dose of Atopic of Inciting Clinical number/ pattern acetaminophen etoricoxi etoricoxib Treatment Disease chronic NSAID(s) reaction sex/age intolerance b which triggered urticaria the reaction Multiple Facial 1/F/28 R, A - SR - + 120 mg NSAIDs urticaria mefenamic 2/F/35 R - CR Facial edema + + 30 mg - All patients acid were given Periorbital 3/M/44 - - ketoprofen SR - + 120 mg antihistamines edema - None needed -Periorbital resuscitation edema or epinephrine -Dizziness administration for <10 Multiple - Reaction 4/M/49 R, AD + CR seconds - + 30 mg NSAIDs resolved -No evidence within 4 hours of cardio- pulmonary compromise Abbreviations: A, asthma; AD, Atopic dermatitis; OPT, oral provocation test; R, rhinitis #Drug pattern: A single-reactor (SR) is defined as a patient with clinical reaction to only one type of NSAID, while a cross-reactor (CR), to more than one type of NSAID, including acetaminophen. Etoricoxib was tolerated by 70 (95%) of our while 1 had both cutaneous and respiratory symptoms. patients. The 4 subjects who reacted to the Furthermore, of the 121 subjects available for provocation test only had mild reactions consisting follow-up, 52 patients took etoricoxib subsequently, of periorbital and facial edema, urticaria and with only 2 patients having reactions, characterized transient giddiness. All these resolved with as very mild lip swelling that resolved antihistamines. There were no subjects needing spontaneously. The tolerability rate of this study was resuscitation or epinephrine administration. Table 2 comparable to the study done by Quercia. 6,7 shows the clinical characteristics of these patients. Our findings showed similar rates when We have shown that etoricoxib is a safe compared with these 2 studies. The tolerability rate alternative in NSAID intolerant subjects. In a study in our study may have been higher had our maximal done by Quercia et al.
Load more

Recommended publications
  • SBARD – Lithium Nsaids
    SBARD in Relation to Potentially Dangerous Interaction Between Lithium and Anti- Inflammatory Drugs A number of medication incidents have been reported recently concerning the prescribing and administration of non-steroidal anti-inflammatory drugs S (NSAIDs) to patients on lithium. Situation Co-administration of a NSAID or cyclo-oxygenase (COX)-2 inhibitor, with lithium increases the risk of lithium toxicity In the last 6 months (Oct.11-Mar.12) there have been 3 Datix incident reports concerning the prescription of a NSAID for in-patients stabilised on lithium. B In each case the NSAID was prescribed “as required”, which increases the risk Background of lithium toxicity due to irregular administration with no increase in lithium monitoring frequency. NSAIDs and COX-2 inhibitors reduce the renal excretion of lithium via their A action on renal prostaglandins, resulting in increased plasma lithium levels. The level of increase is unpredictable (from 10-400%), and the onset of effect is Assessment variable (few days to several months). Risks are increased in patients with impaired renal function, renal artery stenosis or heart failure, and who are dehydrated or on a low salt diet. Co-prescription of NSAIDs or COX-2 inhibitors with lithium is not an absolute R contra-indication, but should be undertaken with extreme caution and only Recommendation when clinically essential. The risk of lithium toxicity is increased with “as required” or intermittent dosing (e.g. when used for menorrhagia), when the effects are less predictable – regular dosing
    [Show full text]
  • Spondyloarthritis: NMA on Pain Outcome RR111467
    NICE CGTSU Spondyloarthritis: NMA on Pain Outcome RR111467 Spondyloarthritis: NMA on pain outcome CGTSU, Bristol (Edna Keeney and Sofia Dias) The purpose of this analysis was to estimate the comparative effectiveness of the following pharmacological interventions for management of pain associated with axial spondyloarthritis: 1. Indomethacin (Reference) 2. Diclofenac 3. Sulindac 4. Fenoprofen 5. Ketoprofen 6. Flurbiprofen 7. Tenoxicam 8. Piroxicam 9. Celecoxib 200mg 10. Celecoxib 400mg 11. Aceclofenac 12. Naproxen 13. Enteric coated Naproxen 14. Etoricoxib 15. Tolfenamic acid 16. Meloxicam 15mg 17. Placebo 23 studies were included in the analyses. The network diagram is shown in Figure 1. Edna Keeney 1 13/10/2015 NICE CGTSU Spondyloarthritis: NMA on Pain Outcome RR111467 Figure 1. Network Diagram for pain outcome Pain Indomethacin Placebo Diclofenac Meloxicam 15mg Sulindac Tolfenamic acid Fenoprofen Etoricoxib Ketoprofen Enteric coated naproxen Flurbiprofen Naproxen Tenoxicam Piroxicam Aceclofenac Celecoxib 400mg Celecoxib 200mg METHODS In order to take all trial information into consideration, Mixed Treatment Comparison meta-analytic techniques, also termed Network meta-analysis (NMA), were employed. NMA is a generalization of standard pairwise meta-analysis for A versus B trials, to data structures that include, for example, A versus B, B versus C, and A versus C trials.1-3 A basic assumption of NMA methods is that direct and indirect evidence estimate the same parameter, that is, the relative effect between A and B measured directly
    [Show full text]
  • Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective Nsaids, and Acetaminophen in Osteoarthritis: a Mixed Treatment Comparison W.B
    6 The Open Rheumatology Journal, 2012, 6, 6-20 Open Access Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective NSAIDs, and Acetaminophen in Osteoarthritis: A Mixed Treatment Comparison W.B. Stam1, J.P. Jansen2 and S.D. Taylor*,3 1Mapi Group, Houten, The Netherlands 2Mapi Group, Boston, MA, USA 3Merck & Co., Inc., Whitehouse Station, NJ, USA Abstract: Objective: To compare the efficacy of etoricoxib, lumiracoxib, celecoxib, non-selective (ns) NSAIDs and acetaminophen in the treatment of osteoarthritis (OA) Methods: Randomized placebo controlled trials investigating the effects of acetaminophen 4000mg, diclofenac 150mg, naproxen 1000mg, ibuprofen 2400mg, celecoxib 100-400mg, lumiracoxib 100-400mg, and etoricoxib 30-60mg with treatment duration of at least two weeks were identified with a systematic literature search. The endpoints of interest were pain, physical function and patient global assessment of disease status (PGADS). Pain and physical function reported on different scales (VAS or LIKERT) were translated into effect sizes (ES). An ES 0.2 - 0.5 was defined as a “small” treatment effect, whereas ES of 0.5 – 0.8 and > 0.8 were defined as “moderate” and “large”, respectively. A negative effect indicated superior effects of the treatment group compared to the control group. Results of all trials were analyzed simultaneously with a Bayesian mixed treatment comparison. Results: There is a >95% probability that etoricoxib (30 or 60mg) shows the greatest improvement in pain and physical function of all interventions compared. ESs of etoricoxib 30mg relative to placebo, celecoxib 200mg, ibuprofen 2400mg, and diclofenac 150mg were -0.66 (95% Credible Interval -0.83; -0.49), -0.32 (-0.50; -0.14), -0.25 (-0.53; 0.03), and -0.17 (-0.41; 0.08), respectively.
    [Show full text]
  • Analgesic Effect of Etoricoxib Compared to Ibuprofen on Post Endodontic Pain
    Analgesic Effect of Etoricoxib Compared to Ibuprofen on Post Endodontic Pain Zahra-Sadat Madani1, Ali Akbar Moghadamnia2, Ali Panahi3, Arash Poorsattar Bejeh Mir4 1Department of Endodontics, Dentistry School, Babol University of Medical Sciences, Babol, Mazandaran Province, Iran. 2Department of Pharmacology, School of Medicine, Babol University of Medical Sciences, Babol, Mazandaran Province, Iran. 3General Dentist, Private Practice, Mazandaran Province, Babol, Iran. 4Dental Materials Research Center, Dentistry School, Babol University of Medical Sciences, Babol, Mazandaran Province, Iran. Abstract Aims: Etoricoxib is a second-generation selective COX-2 inhibitor. There are a few researches investigating analgesic effect of Etoricoxib in dentistry. Methods: This randomized, double-blind, active-control study included sixty patients with clinical pulpal diagnosis of necrosis of the first mandibular molar and an associated periapical radiolucency who experienced severe pain (more than 60 out of 100 in scale of Visual Analog Scale (VAS). The patients were equally randomized into four groups, who received 60 mg etoricoxib (group 1), 90 mg etoricoxib (group 2), 120 mg etoricoxib (group 3), and 400 mg ibuprofen (group 4). All patients randomly received a single dose of the drug after the first session of the root canal therapy. Using VAS, the severity of pain was recorded 2, 4, 6, 12, 24, 48, and 72 hours after the drug was administered. Results: Changing trends of pain over the time was significant for all groups (P=0.003). In addition, there was not a significant difference between various study arms (P=0.146). Conclusion: The results showed that ibuprofen had a comparable effect with various dosage of etoricoxib and may remain as the choice analgesic for dental pulpal pain.
    [Show full text]
  • Safety of Etoricoxib in Patients with Reactions to Nsaids
    ORIGINAL ARTICLE Safety of Etoricoxib in Patients With Reactions to NSAIDs O Quercia, F Emiliani, FG Foschi, GF Stefanini Allergology High Specialty Unit, General Medicine, Faenza Hospital, AUSL Ravenna, Italy ■ Abstract Background: Adverse reactions to nonsteroidal anti-infl ammatory drugs (NSAIDs) are a frequently reported problem due to the fact that these molecules are often used for control of pain and infl ammation. Although the use of selective inhibitors of cyclooxygenase (COX) 2 helps to prevent some of these adverse reactions, they can have cardiac side effects when taken for prolonged periods. Here we report the safety and tolerability of etoricoxib, a selective COX-2 inhibitor with fewer cardiovascular effects, in patients with adverse reactions to NSAIDs. Patients and methods: We performed placebo-controlled oral challenge with etoricoxib in 65 patients with previous adverse reactions to NSAIDs: 13 to salicylates, 18 to arylpropionic acids, 10 to arylacetic acid, 12 to oxicam and derivates, 8 to pyrazolones, and 4 to acetaminophen (paracetamol). The reported symptoms were urticaria or angioedema in 69%, rhinitis in 3%, and 1 case of anaphylactic shock (1.5%). The challenge was done using the placebo on the fi rst day, half dosage of etoricoxib (45 mg) on the second day, and the therapeutic dose of 90 mg on the third day. The challenge was done in the outpatient department of the hospital and the subjects were monitored for a further 4 to 6 hours after challenge. Results: Oral challenge with etoricoxib was well tolerated in 97% of the patients. Only 2 systemic reactions were reported during the challenge test.
    [Show full text]
  • Etoricoxib 30Mg, 60Mg, 90Mg and 120Mg Film-Coated Tablets
    Package leaflet: Information for the user Etoricoxib 30mg, 60mg, 90mg and 120mg Film-coated Tablets etoricoxib Read all of this leaflet carefully before you start • you have diabetes, high cholesterol, or are a smoker. These taking this medicine because it contains important can increase your risk of heart disease. information for you. • you are a woman trying to become pregnant. • Keep this leaflet. You may need to read it again. • you are over 65 years of age. • If you have any further questions, ask your doctor or If you are not sure if any of the above apply to you, talk to your pharmacist. doctor before taking etoricoxib to see if this medicine is • This medicine has been prescribed for you only. Do not pass suitable for you. it on to others. It may harm them, even if their signs of illness are the same as yours. Etoricoxib works equally well in older and younger adult • If you get any side effects, talk to your doctor or patients. If you are over 65 years of age, your doctor will want pharmacist. This includes any possible side effects not to appropriately keep a check on you. No dosage adjustment is listed in this leaflet. See section 4. necessary for patients over 65 years of age. • The full name of this medicine is Etoricoxib 30mg, 60mg, 90mg and 120mg Film-coated Tablets but within this Children and adolescents Do not give this medicine to children and adolescents under 16 leaflet it will be referred to as Etoricoxib Tablets. years of age. What is in this leaflet Other medicines and Etoricoxib Tablets 1 What Etoricoxib Tablets are and what they are Tell your doctor or pharmacist if you are taking, have recently used for taken or might take any other medicines, including medicines 2 What you need to know before you take obtained without a prescription.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • Inflammatory Drugs
    Solubility of Nonsteroidal Anti- diflunisal, etoricoxib, fenbufen, fentiazac, flufenamic inflammatory Drugs (NSAIDs) in acid, flurbiprofen, ibuprofen, indomethacin, ketopro- Neat Organic Solvents and Organic fen, ketorolac, lornoxicam, mefenamic acid, melox- Solvent Mixtures iam, nabumetone, naproxen, niflumic acid, nimesulide, phenylbutazone, piroxicam, rofecoxib, sodium diclof- William E. Acree enac, sodium ibuprofen, sodium naproxen, sodium J. Phys. Chem. Ref. Data 43, 023102 (2014) salicylate, tenoxicam, tolfenamic acid, and valdecoxib. IUPAC-NIST Solubility Data Series, Volume 102 http://dx.doi.org/10.1063/1.4869683 This IUPAC-NIST Solubility Data Series volume reviews experimentally determined solubility data for 33 non- To access recent volumes in the Solubility Data Series, visit http://jpcrd.aip.org/ and steroidal anti-inflammatory drugs (NSAIDs) dissolved search IUPAC-NIST Solubility Data Series in neat organic solvents and well-defined binary and ternary organic solvent mixtures retrieved from the published chemical and pharmaceutical litera- ture covering the period from 1980 to the beginning of 2014. Except for aspirin (2-acetoxybenzoic acid) and salicylic acid (2-hydroxybenzoic acid), very little Provisional Recommendations physical and chemical property data are available Provisional Recommendations are drafts of IUPAC in the published literature for NSAIDs prior to 1980. recommendations on terminology, nomenclature, and Solubility data are compiled and critically reviewed symbols made widely available to allow interested
    [Show full text]
  • Inflammatory Drugs (Nsaids) for People with Or at Risk of COVID-19
    Evidence review Acute use of non-steroidal anti- inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Publication date: April 2020 This evidence review sets out the best available evidence on acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. It should be read in conjunction with the evidence summary, which gives the key messages. Evidence review commissioned by NHS England Disclaimer The content of this evidence review was up-to-date on 24 March 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. For details on the date the searches for evidence were conducted see the search strategy. Copyright © NICE 2020. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3763-9 Contents Contents ...................................................................................................... 1 Background ................................................................................................. 2 Intervention .................................................................................................. 2 Clinical problem ........................................................................................... 3 Objective ...................................................................................................... 3 Methodology ................................................................................................ 4 Summary of included studies
    [Show full text]
  • PRODUCT INFORMATION Etodolac Item No
    PRODUCT INFORMATION Etodolac Item No. 20833 CAS Registry No.: 41340-25-4 Formal Name: 1,8-diethyl-1,3,4,9-tetrahydro- pyrano[3,4-b]indole-1-acetic acid Synonyms: AY 24236, (±)-Etodolac, NIH 9918, H OH NSC 282126 N O O MF: C17H21NO3 FW: 287.4 Purity: ≥98% UV/Vis.: λmax: 224, 273 nm Supplied as: A crystalline solid Storage: Room temperature Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly Laboratory Procedures Etodolac is supplied as a crystalline solid. A stock solution may be made by dissolving the etodolac in the solvent of choice. Etodolac is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of etodolac in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of etodolac can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of etodolac in PBS, pH 7.2, is approximately 0.25 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Etodolac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits both COX isoforms in vitro, with modest selectivity for COX-2 (IC50s = 12 µM for COX-1 and 2.2 µM for COX-2 in a human whole blood assay).1 Experimental evidence suggests that etodolac may have favorable tissue pharmacokinetics resulting in further COX-2 selectivity, indicated by favorable reduction in anti-inflammatory action with diminished gastric side effects.2,3 References 1.
    [Show full text]
  • Results of the Etoricoxib Versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) Trial
    Gastrointestinal Side Effects of Etoricoxib in Patients with Osteoarthritis: Results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) Trial HERBERT S.B. BARAF, CARLOS FUENTEALBA, MARIA GREENWALD, JAN BRZEZICKI, KATHERINE O’BRIEN, BETH SOFFER, ADAM POLIS, STEVEN BIRD, AMARJOT KAUR, and SEAN P. CURTIS, for the EDGE Study Group ABSTRACT. Objective. To compare the gastrointestinal (GI) tolerability, safety, and efficacy of etoricoxib and diclofenac in patients with osteoarthritis (OA). Methods. In total, 7111 patients (mean age 64 yrs) diagnosed with OA were enrolled in a randomized, double-blind trial. Patients received etoricoxib 90 mg qd (n = 3593) or diclofenac sodium 50 mg tid (n = 3518). Gastroprotective agents and low-dose aspirin were prescribed per treatment guidelines. The primary endpoint was the cumulative rate of discontinuations due to clinical and laboratory GI adverse experiences (AE). General safety was assessed, including adjudication of thrombotic cardiovascular (CV) safety data. Efficacy was evaluated using the least-square (LS) mean change from baseline patient global assessment of disease status (PGADS; 0–4 point scale). Results. Mean (SD, maximum) duration of treatment was 9.3 (4.4, 16.5) and 8.9 (4.5, 16.6) months in the etoricoxib and diclofenac groups, respectively. The cumulative discontinuation rate due to GI AE was significantly lower with etoricoxib than diclofenac [9.4 vs 19.2 events per 100 patient-years (PY), respectively; hazard ratio (HR) 0.50 (95% CI 0.43, 0.58; p < 0.001). Rates of thrombotic CV events were similar with etoricoxib and diclofenac [1.25 vs 1.15 events per 100 PY, respectively; HR 1.07 (95% CI 0.65, 1.74)].
    [Show full text]
  • Steroidal Anti-Inflammatory Drugs (Nsaids) in Palliative Care
    GUIDELINES FOR THE USE OF NON- STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN PALLIATIVE CARE 2 9.1 GENERAL PRINCIPLES Non-steroidal anti-inflammatory drugs (NSAIDs) consist of a heterogenous group 1 of compounds that can be subdivided by virtue of their pharmacology: − Non-selective NSAIDs inhibit both COX-1 and COX-2 receptors e.g. ibuprofen, naproxen. − COX-2 selective NSAIDs display some selectivity for COX-2 receptors but this diminishes as the dose increases e.g. etodolac, meloxicam. − COX-2 inhibitors specifically inhibit COX-2 receptors at therapeutic doses whilst being COX-1 sparing e.g. celecoxib, etoricoxib. All NSAIDs have significant cardiovascular and gastrointestinal toxicity. 2 Consider whether alternative treatment would be appropriate (e.g. topical NSAIDs, paracetamol, tramadol). 1 3 Prescribe the lowest effective dose of NSAID for the shortest time necessary. 29.2 GUIDELINES 29.2.1 Cardiovascular risk and NSAID prescribing COX-2 inhibitors are contraindicated for use in patients with established ischaemic heart disease and / or cerebrovascular disease, and also in patients with peripheral arterial disease. 4 [Level 1] Despite conflicting evidence, non-selective NSAIDs and COX-2 selective NSAIDs are currently licensed for use in these groups of patients, although they should be used with caution. 1 [Level 4] 29.2.2 Renal dysfunction and NSAID prescribing Renal function should be assessed prior to the introduction of a NSAID and within 7 days of starting treatment or increasing the dose. 5, 6 [Level 4] Care is required when prescribing NSAIDs for patients with heart failure, ascites or impaired renal function, particularly those who are dehydrated or have a low effective circulating volume.
    [Show full text]